Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis.
Inhibitors of tumor necrosis factor-alpha (TNF-alpha) have been approved for treating rheumatoid arthritis. As one of the biological response modifiers, etanercept has also been used in the treatment of psoriatic arthritis and inflammatory bowel disease. While etanercept is effective, certain infectious complications, such as tuberculosis, fungus, and cytomegalovirus, have been reported. We report the first Korean case of adenoviral pneumonia in a 55-year-old female who developed disseminated adenoviral infection following etanercept treatment, which resolved after anti-TNF-alpha discontinuation.
Kang
Min-Jung
MJ
Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
Kim
Myung-Sin
MS
Choi
Eun-Hwa
EH
Lee
Kyoung-Eun
KE
Kim
You-Kyoung
YK
Choi
Hee-Jung
HJ
D000258:Adenovirus Infections, Human / Q000209:etiology* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000276:immunology; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000068800:Etanercept